Sustained Remission With Atezolizumab in a Frail, Geriatric Patient With Advanced‐Stage Large Cell Neuroendocrine Carcinoma Lung
Open Access
- 1 January 2025
- journal article
- case report
- Published by Wiley in Case Reports in Oncological Medicine
- Vol. 2025 (1) , 2406678
Abstract
Large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive cancer primarily found in the lungs but can also occur in other organs. It is characterized by rapid progression and high metastatic potential. We present a case of advanced‐stage LCNEC lung in a patient with a poor performance status (PS), requiring oxygen support. Imaging revealed a large right upper lobe mass, lymphadenopathy, with bronchial encasement and invasion into the superior vena cava, leading to SVC syndrome and pleural effusion. Biopsy and immunohistochemistry confirmed LCNEC. Due to the patient’s poor PS, treatment began with low‐dose single‐agent chemotherapy (carboplatin), followed by etoposide and cisplatin after improvement. Local radiation was also administered, and the treatment plan was adjusted to include atezolizumab. After 10 cycles, the patient achieved complete remission, sustained for 6 years. This case highlights the complexities of managing advanced LCNEC in a geriatric patient and the effectiveness of a multidisciplinary approach and immunotherapy.Keywords
This publication has 12 references indexed in Scilit:
- Durable Response to Atezolizumab in Extensive-Stage Small-Cell Lung Cancer Leading to 60 Months Overall Survival: A Case ReportCurrent Oncology, 2024
- 2190P First-line atezolizumab in combination with platinum etoposide in patients with metastatic lung large cell neuroendocrine carcinoma (LCNEC)Annals of Oncology, 2023
- Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIANESMO Open, 2022
- Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumabCancer Reports, 2021
- Role of Immunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the LungAsian Pacific Journal of Cancer Prevention, 2021
- American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLCJournal of Thoracic Oncology, 2021
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future ResearchAmerican Society of Clinical Oncology Educational Book, 2018
- The 2015 World Health Organization Classification of Lung TumorsJournal of Thoracic Oncology, 2015
- Chemotherapy for pulmonary large cell neuroendocrine carcinoma: Similar to that for small cell lung cancer or non-small cell lung cancer?Lung Cancer, 2012